Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients

Lung Cancer

Volumn 85, Issue 1, 2014, Pages 19-24

  Kuiper, J L ^a   Heideman, D A M ^a   Thunnissen, E ^a   Paul, M A ^a   van Wijk, A W ^a   Postmus, P E ^a   Smit, E F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

EGFR mutation; NSCLC; Rebiopsy; T790M mutation; Targeted therapy; TKI resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; DISEASE COURSE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENETICS; INCIDENCE; KAPLAN MEIER METHOD; LUNG; LUNG NEOPLASMS; MIDDLE AGED; MISSENSE MUTATION; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION, MISSENSE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84901602817     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.03.016     Document Type: Article

References (29)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(January (1)):10-29.
2. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saoijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(September (10)):947-957.
3. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361(September (10)):958-967.
4. Yun C.H., Mengwasser K.E., Toms A.V., Moo M.S., Greukich H., Wong K.K., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008, 105(February (6)):2070-2075.
5. Sequist L.V., Waltman B.A., as-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(March (75)):75ra26.
6. Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowki M.F., Pao W., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013, 19(April (8)):2240-2247.
7. Arcila M.E., Oxnard G.R., Nafa K., Riely G.J., Solomon S.B., Zakowski M.F., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011, 17(March (5)):1169-1180.
8. Sun J.M., Ahn M.J., Choi Y.L., Ahn J.S., Park K. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer 2013, 82(2):294-298.
9. Hata A., Katakami N., Kaji R., Fujita S., Imai Y. Does T790M disappear? Successful gefitinib rechallenge after T790M disappearance in a patient with EGFR-mutant non-small-cell lung cancer. J Thorac Oncol 2013, 8(March (3)):e27-e29.
10. Eisenhauer E.A., Therasse P., Bogaerts J., Schwarts L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(January (2)):228-247.
11. Heideman D.A., Thunnissen F.B., Doeleman M., Kramer D., Verheul H.M., Smit E.F. A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes. Cell Oncol 2009, 31(5):329-333.
12. Kramer D., Thunnissen F.B., Gallegos-Ruiz M.I., Smit E.F., Postmus P.E., Meijer C.J., et al. A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations. Cell Oncol 2009, 31(3):161-167.
13. Heideman D.A., Lurkin I., Doeleman M., Smit E.F., Verheul H.M., Meijer G.A., et al. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn 2012, 14(May (3)):247-255.
14. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366(March (10)):883-892.
15. Oxnard G.R., Arcila M.E., Chmielecki J., Ladanyi M., Miller V.A., Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011, 17(September (17)):5530-5537.
16. Fujita Y., Suda K., Kimura H., Matsumoto K., Arao T., Nagai T., et al. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol 2012, 7(November (11)):1640-1644.
17. Su K.Y., Chen H.Y., Li K.C., Kuo M.L., Yang J.C., Chan W.K., et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012, 30(February (4)):433-440.
18. Ye X., Zhu Z.Z., Zhong L., Lu Y., Sun Y., Yin X., et al. High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?. J Thorac Oncol 2013, 8(September (9)):1118-1120.
19. Chmielecki J., Foo J., Oxnard G.R., Hutchinson K., Ohashi K., Somwar R., et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011, 3(July (90)):90ra59.
20. Morinaga R., Okamoto I., Furuta K., Kawano Y., Sekijima M., Dote K., et al. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 2007, 58(December (3)):411-413.
21. Popat S., Wotherspoon A., Nutting C.M., Gonzalez D., Nicholson A.G., O'Brien M. Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Lung Cancer 2013, 80(April (1)):1-4.
22. Zakowski M.F., Ladanyi M., Kris M.G. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006, 355(July (2)):213-215.
23. Zhang Y., Li X.Y., Tang Y., Xu Y., Guo W.H., Li Y.C., et al. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?. Lung Cancer 2013, 81(August (2)):302-305.
24. Janjigian Y.Y., Groen H.J., Horn L., Smit E.F., Fu Y., Wang F., et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 2011, 29. [suppl; abstr 7525].
25. Ranson M., Pao W., Kim D.W., Kim S.W., Ohe Y., Felip E., et al. AZD9291: an irreversible, potent and selective tyrosine kinase inhibitor (TKI) of activating (EGFRm+) and resistance (T790M) mutations in advanced NSCLC. J Thorac Oncol 2013, 8(Suppl. 2):S389. [abstr MO21. 12].
26. Soria J.C., Sequist L.V., Gadgeel S., Goldman J., Wakelee H., Varga A., et al. First-in-human evaluation of CO-1686, an irreversible, highly, selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Thorac Oncol 2013, 8(Suppl. 2):S141-S142. [abstr O03. 06].
27. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006, 12(October (19)):5764-5769.
28. Ohashi K., Sequist L.V., Arcila M.E., Moran T., Chmielecki J., Lin Y.L., et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 2012, 109(July (31)):E2127-E2133.
29. Takezawa K., Pirazzoli V., Arcila M.E., Nebhan C.A., Song X., de, Stanchina E., et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012, 2(October (10)):922-933.